MAA Life cycle management

Marketing Authorization Application & Life-cycle-management

Marketing Authorization Application (MAA)

A Marketing Authorization Application (MAA) is a comprehensive document submitted by pharmaceutical companies to regulatory authorities to obtain approval for marketing and distributing a medicinal product. In the European Union the MAA is assessed by the European Medicines Agency, if applicable, or by the national Authority of a member state.

The MAA process is complex and requires careful preparation and attention to detail ensuring accuracy and quality in work.

The MAA consists of several modules, including:

      1. Module 1: EU Administrative and Prescribing Information
      2. Module 2: High-Level Summaries
      3. Module 3: Quality Documentation
      4. Module 4: Non-Clinical Documentation
      5. Module5: Clinical Documentation

Depending on the nature of the medicinal product and the strategy of the applicant there are four procedures for filing an application:

      • Centralized Procedure
      • National Procedure
      • Mutual Recognition Procedure
      • Decentralized Procedure

Post MAA Life Cycle Management/ Variations and Renewals

Maintaining a state-of-the art marketing authorization (MA) for medicinal products in Europe requires ongoing regulatory activities to ensure compliance with current requirements and to incorporate new information about the product.

Variations:

Variations are any changes made to an existing MA after its initial approval. These can include:

      • Administrative changes
      • Quality changes
      • Safety and efficacy updates
      • Pharmacovigilance modifications

The European Commission Regulation (EC) No 1234/2008 classifies variations into different types:

      • Type IAIN, Type IA, Type IB, Type II, Extensions of MA and Article 61(3) notifications

The classification determines the timeline and level of assessment required.

Renewals

Initial MAs in Europe are typically valid for five years. Key aspects of the renewal process include:

      • Applications must be submitted at least nine months before expiry
      • Renewal applications undergo formal assessment
      • Once renewed, MAs are usually valid indefinitely
      • Authorities may require one additional five-year renewal in some cases

For centralized procedures, renewals are based on Article 14 of EC Regulation No. 726/2004

As a solution, we offer:

MAA

  • Manage all aspects of Marketing Authorization Applications (MAAs), variations, and renewals for medicinal products in the European Union.
  • Develop regulatory strategy for new MAA (Rx, OTC, Generics)
  • Strategic regulatory advice for lifecycle management
  • Preparation of all required modules of the Common Technical Document (eCTD)
  • Compilation of comprehensive dossiers for full stand-alone or abridged applications
  • Ensure compliance with all regulatory requirements

Variations / post-approval changes

  • Classification of variations according to The European Commission Regulation (EC) No 1234/2008 (Type IA, Type IB, or Type II)
  • Preparation and submission of variation applications
  • Liaison with health authorities throughout the variation process

Renewals

  • Timely preparation and submission of renewal applications
  • Compilation of required documentation, including updated benefit-risk assessments
  • Management of the renewal process with health authorities

Additional Services

  • Promotional and educational materials review
  • Product Information review (SmPC, leaflets and labeling) according to the Quality Review of Documents ‘QRD’ templates
  • Packaging/artworks review
  • CMC Compliance (Module 3 gap analysis, Nitrosamines assessment, ….)
art008
sqr021-col1
sqr021-col2

Get in Touch

Have questions or need expert guidance on regulatory compliance? We’re here to help! Contact us today to discuss how NTLS can support your business.